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Abstract
Background: Depression, chronic pain and opioid dependence are conditions commonly
encountered in primary care settings. These comorbidities create treatment challenges while
negatively influencing outcomes of care. The Patient Health Questionnaire (PHQ9) and Global
Pain Scale (GPS) are valid screening tools used to score depression and pain symptoms. The
purpose of this study was to determine the relationship between the PHQ9 and Global Pain Scale
(GPS) scores in opioid dependent adults with chronic pain to determine whether both tools are
necessary.

Methods: This was a descriptive study using a retrospective correlational research design. Data
was obtained from the electronic medical records (EMR) of 44 patients enrolled in a Chronic
Opioid Analgesic Therapy (COAT) clinic between August 1, 2016 and July 31, 2017. Privacy
was maintained through de-identification of data. The variables were analyzed using SPSS
statistical software after all data was collected.

Results: A significant and positive correlation exists between the PHQ9 and GPS total scores (r
= .63). In addition, all the sub scores of the Your Activities and Your Clinical Outcomes of the
GPS were statistically significant and positively correlated to the PHQ9 at p = <0.05.

Conclusion: Understanding the relationship between the PHQ9 and GPS scores in adults with
chronic pain and opioid dependence can improve depression screening and reduce respondent
fatigue. The results of this study indicate the GPS may be sufficient to screen for depression, and
the PHQ9 could be eliminated from the screening process.
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Evaluating the Relationship Between PHQ9 and Global Pain Scale (GPS) Scores in Opioid
Dependent Adults at the Polk Dalton Clinic
Introduction
Patients with chronic pain, depression and substance use disorders (SUD) are routinely
treated in primary care. Approximately 52% of primary care patients are diagnosed with chronic
pain (>3months), 5-13% have depression and 19% have a SUD (Barrett & Chang, 2016). These
health issues are multidimensional and complicated by the fact that 50% of patients with
depression and 65% with substance use disorders are undiagnosed or do not seek help (Barrett &
Chang, 2016). The overlapping of depression, chronic pain and substance use, such as opioid
dependence, presents treatment challenges to healthcare providers.
The US Preventive Services Task Force (USPSTF) recommends screening for depression
in the adult population (age 18 or older) regardless of risk factors (Siu, 2016). This Grade B
recommendation states depression screening should be performed with systems in place to
provide “accurate diagnosis, effective treatment, and appropriate follow-up” (Siu, 2016, pg.
382). In this study, opioid dependent adults with chronic pain at a primary care clinic were
screened for depression and pain symptoms using the Patient Health Questionnaire (PHQ9) and
the Global Pain Scale (GPS) tools at each visit. The purpose of this DNP project is to determine
the relationship between the PHQ9 and GPS scores in order to improve screening efficiency by
eliminating unnecessary screening tools and decreasing survey response fatigue.
Background
Depression affects 350 million people worldwide, and fewer than half of all those who
are diagnosed with depression receive treatment (WHO, 2016). The extensive influence
depression has on medical conditions, behaviors and outcomes of care can make treatment
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challenging. Also, there is a strong association between physical and mental health (WHO,
2016). Depression has been shown to contribute to negative health behaviors in adults, such as
obesity and smoking, and it is associated with many chronic diseases and conditions including
diabetes, hypertension, stroke, heart disease, and cancer (CDC, 2016). The presence of
depression and a co-existing health condition can affect functioning, quality of life, utilization of
health care services, and health care costs (Barrett & Chang, 2016).
Chronic pain affects 100 million Americans, and is associated with poor social
relationships, isolation, financial problems, and depression (Barrett & Chang, 2016). In addition,
Barrett & Chang (2016) report the prevalence of substance use disorders (SUD) in patients with
chronic pain is estimated at 48%. The authors state a diagnosis of depression along with chronic
pain can increase pain intensity, disability, and negatively influence the clinical outcomes of pain
treatment. The association between chronic pain, depression and substance use can interfere
with effective depression diagnosis, treatment and outcomes of care (Barrett & Chang, 2016).
The National Institutes of Health (NIH) recommends utilizing behavioral health interventions in
primary care settings where the comorbidities of opioid dependence, chronic pain and depression
are present (Barrett & Chang, 2016).
Primary care providers may prescribe opioids to manage chronic pain with three to four
percent of adults on long-term opioid therapy in the United States (Dowell, Haegerich, & Chou,
2016). More than 650,000 opioid prescriptions are written each day (HHS, 2016). The ethical
and safety issues surrounding the prescribing of opioids for chronic pain include complications
related to abuse and overdose (Dowell et al, 2016). Primary care providers must adopt measures
to safely prescribe opioids for chronic pain without contributing to the growing problem of
opioid dependence, abuse and related deaths from opioid misuse. An estimated 1.9 million
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people were dependent on or abused prescription opioid medications in 2013 (Dowell et al.,
2016), and prescription opioids were to blame for nearly half of all opioid overdose deaths in
2016 (CDC, 2018).
Opioids are effective and safe for the treatment of chronic pain in patients who are
candidates for long-term use. Ballantyne (2015) states low doses of opioids can decrease pain
and improve function in elderly patients with arthritis who cannot tolerate alternative treatments.
The author also reports patients with serious disease states who have not restored function with
other forms of treatment can also benefit from opioids. Suitable candidates must be screened and
selected based on risk assessment and a complete history and physical to ensure safe treatment
(Ballantyne, 2015). The decision to treat with chronic opioid therapy should be based on the
benefits versus risk along with implementing written agreements and routine monitoring to help
prevent misuse and abuse of opioids (Ballantyne, 2015).
The onsite Chronic Opioid Analgesic Therapy (COAT) clinic at an urban primary care
medical office safely provides opioid treatment for patients with a chronic pain diagnosis.
Acceptance into the COAT clinic is determined on an individual basis. The patients are required
by contract to visit the clinic once a month where they are screened for depression and pain
along with receiving a monthly prescription for opioids. It is important to screen this patient
population for depression as many individuals with chronic pain often have depressive symptoms
(Boakye et al., 2016).
Furthermore, depression increases pain intensity and often accompanies opioid use in
adults with chronic pain (Barrett & Chang, 2016). Opioid dependent adults diagnosed with
chronic pain and depression benefit from collaborative health treatments provided by a team of
medical and nursing professionals, along with psychological and social work interventions
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(Barrett & Chang, 2016). A barrier to effective treatment of depression is inaccurate assessment
and diagnosis (WHO, 2016). Hence, it is important to effectively screen and accurately diagnose
depression in opioid dependent adults.
Screening tools can play a significant role in identifying those individuals at risk for
depression. The Patient Health Questionnaire (PHQ9) is used to screen COAT clinic patients for
depression symptoms at each monthly visit. It is a tool approved by the USPSTF for depression
screening in adults (Siu, 2016). The PHQ9 can screen, diagnose, monitor and measure the
severity of depression over time by rating the frequency of symptoms. Positive PHQ9 screenings
should be followed up with additional assessments of depression severity and other
psychological problems, such as anxiety (Siu, 2016).
The Global Pain Scale (GPS) is also administered at each COAT clinic visit to screen for
pain, functioning and emotional well-being. This screening tool gives information on how
chronic pain affects daily life. The evaluation of the correlation between the PHQ9 and GPS can
improve the screening process in opioid dependent adults who suffer from chronic pain and
depression. The use of only one of these tools may be all that is necessary to accurately screen
for symptoms of depression.
Theoretical Framework
For this study, certain determinants of the theory of planned behavior can be used to
understand individual habits and behaviors related to screening. Aizen, 1991 states the three
determinants of this theory are attitude toward the behavior, subjective norms, and perceived
behavior control. The author defines attitude toward the behavior as the extent to which the
patient believes the behavior is beneficial or not, and the subjective norm as the social pressure
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felt to perform the behavior. The third determinant is perceived behavior control, which is
whether the individual feels the behavior will be easy or difficult to perform (Ajzen, 1991).
All three determinants interact to influence and predict intentions to engage in certain
behaviors. Shah, Scogin, Pierpaoli, and Shah (2018) found both attitudes and subjective norms
were strong predictors of willingness to complete depression screenings. The authors found most
adults were receptive and felt there was a benefit to depression screening. Increasing subjective
norms through education was also a strong predictor of screening acceptance (Shah et al. (2018).
Perceived behavior control has not been shown to affect screening behaviors in a study
completed by Breau, (2014).
Purpose
The monthly screening of COAT clinic patients with two screening tools at each visit
raises the issue of poor response reliability due to survey respondent fatigue. Appropriate time
intervals for screenings are not known (Siu, 2016); however, monthly screening with two tools
could be burdensome for patients. The purpose of this project is to evaluate and compare the
screening scores of the PHQ9 and the GPS in opioid dependent adults with chronic pain. The
purposeful examination of these screening tools may eliminate overlap and repetition of
depression screening to prevent survey fatigue.
The primary objectives are:
1. Describe the patient population in the Chronic Opioid Analgesic Therapy (COAT) clinic
patients in terms of demographics (gender, age, ethnicity), depressive symptoms, and
pain scores (GPS, Current Pain Level (CPL) and Acceptable Pain Level (APL))
2. Examine the relationship between depressive symptoms (using PHQ9) and pain scores
(using the GPS) in the COAT Clinic patients
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3. Determine the relationship between demographics (gender, age, ethnicity) and depressive
symptoms (using the PHQ9) and pain scores (using the GPS) in the COAT Clinic
patients.
4. Determine if acceptable pain level (scale ranging 0-10) correlates to depressive
symptoms (using PHQ9) in the COAT clinic patients.
5. Determine the correlation between pain level (scale ranging 0-10) and depressive
symptoms (using PHQ9) with the clinical outcomes and activities (using the GPS) in the
COAT clinic patients.
Methods
Study Design
This study utilized a correlational study design to determine the relationship between the
PHQ9 and GPS scores in the COAT clinic patients. A correlation analysis describes the strength
and direction of the linear relationship between two variables (Pallant, 2016). A retrospective
review of electronic medical records provided the data used in the analysis.
Sample Selection and Site
A primary care medical office in an urban setting was the site for this study. This primary
care clinic offers family medical services across the life span. The sample for this study was
obtained by extracting de-identified data from the electronic medical record (EMR) of Chronic
Opioid Analgesic Therapy (COAT) clinic patients. All adult COAT clinic patients seen between
August 1, 2016 and July 31, 2017 were included in the sample. Patients who did not complete
the PHQ9 or GPS were excluded from the study. The sample size was 44 patients.
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Measures
The PHQ9 has 9 questions in a self-report tool incorporating DSM-IV depression
diagnostic criteria. The frequency of symptoms are scored with a score of 5-9= minimal
symptoms, 10-14= minor depression, dysthymia, mild depression, 15-19= major depression,
moderately severe, >20= major depression, severe (CDC, 2016). The PHQ9 screening scores of
10 or higher have a sensitivity of 88% and a specificity of 88% for major depressive disorder
(Savoy & O’Gurek, 2016).
The Global Pain Scale (GPS) assesses the physical and psychological impact of chronic
pain on the individual. It is a simple and easy method to measure and track pain and treatment
outcomes. This screening tool utilizes an eleven-point Likert scale (0-10) with 4 subscales: your
pain, your feelings, your clinical outcomes, and your activities (Gentile, Woodhouse, Lynch,
Maier and McJunkin, 2011). The ‘Your Pain’ subscale asks about current pain, along with the
best, worst and average pain over the past week. The ‘Your Feelings’ subscale asks participants
how they have felt in the past week related to the emotions of being afraid, depressed, tired,
anxious and stressed. The ‘Your Clinical Outcomes’ subscale questions are related to the effect
of chronic pain on sleeping, feeling comfortable, personal independence, working or performing
normal tasks and medication use during the past week. The fourth subscale is ‘Your Activities’,
and it asks whether the individual was able to go to the store, do chores in the home, enjoy
friends and family, exercise and participate in hobbies during the past week.
Each GPS subscale is worth 25 points with a maximum total score of 100. The score is
achieved by adding up the total score and then dividing by two. Higher scores represent
worsened conditions. Gentile et al. (2011) found the total GPS scale reliable (Cronbach alpha
0.89) along with each subscale (pain 0.87,feelings 0.84, clinical outcomes 0.72, and activities
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0.96). This screening tool has significant and moderate inter-correlations between subscales,
which indicates high construct and criterion validity (Gentile et al, 2011). Therefore, the GPS
and its subscales provide a good option for a reliable and valid method to screen for pain and
depressive symptoms.
Acceptable Pain Level (APL) was recorded as the level of pain that is acceptable to the
patient. It was measured with a scale of 0-10. The Current Pain Level (CPL) was the subjective
level of pain at the time of the visit measured using a scale of 0-10. For both of these measures,
a score of zero would be “no pain”, and a score of ten would be “the worst possible pain”.
Demographic variables were also collected to describe the sample. They included gender,
age and ethnicity.
Procedures
Data collection for this study did not involve direct contact or intervention with the
subjects, so informed consent was not necessary. The principal investigator was the sole
researcher, and all EMR data extraction was performed on a desktop computer at the primary
care clinic under the direct supervision of the COAT clinic director. Data extraction occurred
from November 2017 to April of 2018. The patient visit within this time frame that included both
PHQ9 and GPS scores was the dated used to extract study variables. Data was extracted and
placed in an Excel spreadsheet. The spreadsheet and all relevant study variables were stored on
an encrypted USB drive. The data was de-identified, and the confidentiality of the subject’s
personal health information (PHI) was maintained. Human subjects exempt approval was
obtained from the University of Kentucky Office of Research Integrity.
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Statistical Analysis
Data was analyzed using SPSS software. The variables were summarized using
descriptive statistics. The association or relationship between variables was tested with Pearson
product moment correlation, Spearman’s rho, and two sample t-tests (Levene’s Test for Equality
of Variances). Equal variances were assumed for the t-tests. Significance level was set at 0.05.
Statistical analysis occurred at the completion of data collection.
Results
Demographics
The patient population was described using demographics, depressive symptoms, and
pain scores (Objective 1). Forty-four charts were reviewed and demographic variables included
gender, age and ethnicity. Females accounted for 77% (n=34) of the sample. Those between the
ages of 56-65 years old represented 43.2% of the sample. The sample was evenly divided
between Caucasians and African Americans.
The continuous variables of PHQ9, GPS, APL, and CPL were summarized using
frequencies along with the mean and standard deviation. The majority of COAT clinic patients
(68%) reported minimal to mild symptoms of depression on the PHQ9. Eight patients (18.2%)
had moderate depressive symptoms and six individuals (13.6%) reported moderate to severe
symptoms. There were no severe depression screening scores
The descriptive analysis of pain scores resulted in a GPS total score mean of 31(18.31).
The current pain level mean was 6.23 (2.19), and the APL mean was 5.05 (1.18). In addition, the
means were calculated for the ‘Your Clinical Outcomes’ and ‘Your Activities’ individual
subscales. See Table 1.

10	
  

EVALUATING THE RELATIONSHIP BETWEEN PHQ9 AND GLOBAL
Relationship between PHQ9, Acceptable Pain Level and GPS
The results for objective two indicate a significant and positive correlation between the
overall PHQ9 and the overall GPS scores at 0.000 (r = .63). The relationship between the
Acceptable Pain Level (APL) and PHQ9 (p = .08) was not statistically significant in this sample
(Objective 4). See Table 2.
Table 2. Correlations among PHQ9, Acceptable Pain Level, and GPS
PHQ9
r (p)
.27 (.08)

Acceptable Pain Level (APL)
Global pain score (GPS)

.63(< .001)**

** p = 0.01
Relationship between Demographics and PHQ9 and GPS
The relationship between the sample demographics, PHQ9 and GPS (Objective 3) was
evaluated using group means, standard deviations, Spearman’s rho and independent samples ttests. The results were not statistically significant (Table 3.). The p value at >.05 and the small
rho value indicate a weak correlation between the demographics of age, gender and ethnicity and
the PHQ9 and GPS scores.
Relationship between Current Pain Level, PHQ9 and Activities and Clinical Outcomes
Subscales of the GPS scales
Correlational analysis for Objective 5 illustrated positive and significant correlations
between CPL and the ‘Your Activities’ sub score specifically the item of enjoying friends and
family (r= .41, p =.01). The current pain level also had positive and significant relationships
with the ‘Your Clinical Outcomes’ sub scores related to difficulty sleeping (r =.34, p =.03),
comfort (r=.36, p =.02), and need for medication (r=.35, p =.02) See Table 4. In addition, all of
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the sub scores of the ‘Your Activities’ and ‘Your Clinical Outcomes’ were statistically
significant and positively correlated to the PHQ9 (p = < .05). See Table 5.
Discussion
Key Findings
In this study, the demographic, depressive and pain scores were described for the patients
in the COAT clinic. Relationships were explored between the demographics and PHQ9 and GPS
scores. Significant correlations were found between the PHQ9 and GPS total scores. In addition,
the GPS subscales of ‘Your Clinical Outcomes’ and ‘Your Activities” were positively correlated
with the PHQ9 and Current Pain Levels.
The sample was primarily women, middle aged and equally distributed between African
Americans and Caucasians. These findings are relevant since the prevalence of major depression
is higher in women than in men (Albert, 2015), and chronic pain has been shown to increase
symptoms of depression (Barrett & Chang, 2016). The majority of reported depressive symptoms
were minimal to mild. This may be due to survey respondent fatigue or antidepressant therapy.
Data was not collected to determine those currently treated with either psychotherapy or
pharmacotherapy for depressive symptoms; however, it is well known the use of antidepressant
medications and psychotherapy are effective in reducing depressive symptoms (Cuijpers,
Sijbrandij, Koole, Andersson, Beekman, and Reynolds, 2013).
The total GPS, APL and Current Pain Level scores were moderate. This could be due to
some level of pain control by the prescribed opioid medication. Opioids in low doses can be
helpful to decrease pain in low-risk individuals with a chronic pain diagnosis (Ballantyne, 2015).
Pain management along with depression screening is important for the COAT clinic patients.
Depression and pain are inter-related, and chronic pain can increase symptoms of depression.
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The relationship between pain and depression was evaluated in Objectives 2 and 4 using
the PHQ9, APL and total GPS scores. The close relationship between the PHQ9 and GPS
indicates these two screening tools may be testing the same concepts. In particular, many of the
questions in the GPS are related to emotions and function, which are similar to the PHQ9. The
finding reinforces the close relationship between chronic pain and depression (Burke, Mathias,
and Denson, 2015), and this relationship is present in the research. According to Barrett & Chang
(2016), there is an intricate overlapping of chronic pain and depression pathways in the brain,
and depression can create sensory changes that result in increased pain sensitivity. In contrast to
the GPS, the APL scores do not show a relationship to the PHQ9. No evidence to support a
relationship between APL and depression was found in the literature, but since APL is a
subjective report of an acceptable pain level there may actually be a connection even though this
study does not support it.
The PHQ9 and GPS have no preference or relationship to gender, age or race in this
study (Objective 3). These results do not match literature findings on this topic. Research
suggests older adults and African Americans are at an increased risk for experiencing depression
(CDC, 2018). In addition, the Centers for Disease Control and Prevention (2018) report women
are almost twice as likely to have depressive symptoms than men. The lack of connection
between the PHQ9 and GPS for gender, age and race might be attributed to the adequate control
of pain and depression resulting in lower screening scores. Unreliable screening results due to
response burden and survey fatigue may have affected results as well.
Results suggest depressive symptoms and reported pain level have an effect on daily
activities and functioning (Objective 5). Duenas, Ojeda, Salazar, Mico and Failde (2016) report
chronic pain can have a negative impact on quality of life and daily activities. In particular, the
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authors state there is a strong correlation between chronic pain and decreased physical activity,
such as walking, performing chores around the house and participating in social activities. A
chronic pain diagnosis can cause sleep disturbances, work absenteeism, increased stress levels
and poor mental health (Duenas et al. 2016). Like chronic pain, symptoms of depression were
found to negatively affect quality of life, increase stress and interfere with physical, interpersonal
and social activities (Jayasekara et al. 2015). All ten items of the GPS subscales ‘Your Clinical
Outcomes’ and ‘ Your Activities” correlated with the PHQ9. Interestingly, these ten times are
also symptoms of depression.
Implications for Practice
There is a significant and positive correlation between the PHQ9 and GPS; therefore, an
implication for future practice could be to remove the PHQ9 and only screen with the GPS. This
would prevent test redundancy and problems with over screening. Excessive screening can lead
to inappropriate treatment and may not always improve outcomes (Lenzer, 2017). The benefit
versus harm of depression screening should take into consideration the difference between
treating patients who have clinical depression compared to those who only screen positive
(Lenzer, 2017).
On the other hand, there may be a detriment to patient care if a pain scale is used
exclusively without a depression scale. Providers may only diagnose and treat pain whereas
unidentified depression might be undertreated. Although the USPSTF does not recommend an
ideal screening interval, clinical judgment should be used to determine if more frequent
screenings with the PHQ9 are necessary depending on assessment of individual patient risk
factors (Siu, 2016).
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Further implications for practice could include the addition of an on site psychiatric
APRN who can further evaluate and treat those patients who screen positive for depression. Over
60% of the COAT clinic patients had mild to moderate-severe depressive symptoms. The
assumption is that a decrease in depression symptoms will result in a decrease in pain symptoms
and lower opioid dependence. In addition, diagnosis and treatment of depression can improve
symptoms and quality of life (Barrett & Chang, 2016).
Implications for Future Study
Implications for future study include performing statistical analysis to determine the
relationship between the ‘Your Feelings’ subscale of the GPS and the PHQ9. The ‘Your
Feelings’ subscale measures how pain is affecting the emotional state of the patient (afraid,
depressed, tired, anxious, and stressed) over the past week. This was not addressed in this study,
but it may affect the strength of the correlation between the overall PHQ9 and GPS scores. A
factor analysis between the PHQ9 and GPS scores should also be done to determine PHQ9 and
GPS similarities. Furthermore, data extraction from the EMR about antidepressant use could be
relevant to the screening scores and frequency distribution. The PHQ9 score of those already
being treated with antidepressant therapy may reflect different results than those who are
untreated.
Identifying the relationship between the individual’s dose of opioid pain medication and
the PHQ9 and GPS screening scores would also be of interest. It is well known chronic use of
opioids is associated with depression, and those patients with depression are nearly twice as
likely to use opioids for long-term pain relief (Davis, Lin, Liu and Sites, 2017). Increased opioid
use in individuals with symptoms of depression can help identify the potential for adverse opioid
treatment outcomes, such as misuse and overdose. (Davis et al. (2017)..
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Limitations
There were several limitations identified with this study. For example, this study has a
small sample size (N=44) and was conducted in one clinical setting. Therefore, the results may
not be transferable or generalized to a larger population or setting. Also, the PHQ9 and GPS are
validated screening tools, but repeated screening exposures may lead to desensitization resulting
in unreliable scores. Furthermore, these screening tools are self-reported and subjective which
increases the risk of response bias. Finally, there were at least three separate health care
providers documenting screening scores in the EMR, which may have resulted in inconsistent
data entry errors.
Conclusion
Patients with chronic pain, depression and opioid dependence present clinical treatment
challenges in primary care. The PHQ9 and the GPS are reliable tools used to regularly screen for
depression and chronic pain symptoms in this patient population. The administration of two
screening tools at the monthly COAT clinic visit may not be necessary and can lead to excessive
screening and inappropriate treatment. The results of this study show the GPS alone may be
sufficient to screen for depression. Eliminating or decreasing screening frequency with the
redundant PHQ9 could help lower survey respondent fatigue and improve response reliability
and screening effectiveness in opioid dependent adults with chronic pain. This practice change
may also enhance chronic pain management.
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Table 1. Characteristics of Sample (N=44)
N= 44
Gender
Female
Male
Age
26-35
36-45
46-55
56-65
66-75
76-85
86+
Ethnicity
Caucasian
African Am
Other
PHQ9
Total
Minimal 0-4
Mild 5-9
Mod 10-14
Mod-Sev 10-14
Severe >14

Mean (SD) or n (%)
34 (77.3%)
10 (22.7%)
0 (0.0%)
5 (11.4%)
5 (11.4%)
19 (43.2%)
13 (29.5%)
2 (4.5%)
0 (0.0%)
22 (50.0%)
22 (50.0%)
0 (0.0%)
3.57 (4.11)
15 (34.1%)
15 (34.1%)
8 (18.2%)
6 (13.6%)
0 (0.0%)

Total GPS

31.00 (18.31)

Clinical Outcomes
During the Past week:
I had trouble sleeping
I had trouble feeling comfortable
I was less independent
I was unable to work (do normal tasks)
I needed to take more medication
Activities
During the past week I was NOT able to:
Go to the store
Do chores in my home
Enjoy my friends and family
Exercise (including walking)
Participate in my favorite activities
Current Pain Level
Acceptable Pain Level

2.12 (2.85)
2.65 (3.24)
2.28 (3.25)
2.67 (3.79)
1.86 (3.31)
2.37 (3.24)
2.70 (3.43)
2.00 (2.96)
3.14 (3.73)
2.53 (3.57
6.23 (2.19)
5.05 (1.18)
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Table 3. Correlations among demographics, PHQ9 and GPS
Demographic
PHQ 9
Global Pain Scale
characteristics
test statistic
p
test statistic
P
Age

Gender
Female
Male
Ethnicity
White
African Amer

rho= -.18

.24

rho= -.13

.39

Mean (SD)

p

Mean (SD)

P

3.56 (4.05)
3.60 (4.53)

.691

31.88 (18.11)
27.98 (19.68)

.750

.524
1.41 (4.34)
3.73 (3.95)

.422
26.63 (16.98)
35.36 (18.93)

Table 4. Correlations among Current Pain Level, Activities and Clinical Outcomes
Current Pain level
r(p)
Your Activities
Go to the store
.17(.29)
Do chores in my home
.15(.33)
Enjoy my friends and family
.41(.01)**
Exercise (including walking)
.23(.14)
Participate in my favorite hobbies
.25(.11)
Your Clinical outcomes
I had trouble sleeping
.34(.03)*
I had trouble feeling comfortable
.36(.02)*
I was less independent
.16(.30)
I was unable to work (or perform normal tasks)
.07(.70)
I needed to take more medication
.35(.02)*
** p = 0.01 level
* p = 0.05 level

18	
  

EVALUATING THE RELATIONSHIP BETWEEN PHQ9 AND GLOBAL

Table 5. Correlations among PHQ9, Clinical Outcomes and Activities
PHQ9
r(p)
Your Activities
Go to the store
Do chores in my home
Enjoy my friends and family
Exercise (including walking)
Participate in my favorite hobbies
Your Clinical outcomes
I had trouble sleeping
I had trouble feeling comfortable
I was less independent
I was unable to work (or perform normal tasks)
I needed to take more medication
** p = 0.01 level
* p = 0.05 level

.53(.00)**
.35(.02)*
.55(.00)**
.47(.00)**
.56(.00)**
.53(.00)**
.64(.00)**
.60(.00)**
.48(.00)**
.34(.03)*
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Image 1. Patient Health Questionnaire (PHQ9)

PATIENT HEALTH QUESTIONNAIRE-9
(PHQ-9)
Over the last 2 weeks, how often have you been bothered
by any of the following problems?
(Use “✔” to indicate your answer)

Not at all

Several
days

More
than half
the days

Nearly
every
day

1. Little interest or pleasure in doing things

0

1

2

3

2. Feeling down, depressed, or hopeless

0

1

2

3

3. Trouble falling or staying asleep, or sleeping too much

0

1

2

3

4. Feeling tired or having little energy

0

1

2

3

5. Poor appetite or overeating

0

1

2

3

6. Feeling bad about yourself — or that you are a failure or
have let yourself or your family down

0

1

2

3

7. Trouble concentrating on things, such as reading the
newspaper or watching television

0

1

2

3

8. Moving or speaking so slowly that other people could have
noticed? Or the opposite — being so fidgety or restless
that you have been moving around a lot more than usual

0

1

2

3

9. Thoughts that you would be better off dead or of hurting
yourself in some way

0

1

2

3

FOR OFFICE CODING

0

+ ______ + ______ + ______
=Total Score: ______

If you checked off any problems, how difficult have these problems made it for you to do your
work, take care of things at home, or get along with other people?
Not difficult
at all

Somewhat
difficult

Very
difficult

Extremely
difficult

Developed by Drs. Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke and colleagues, with an educational grant from
Pfizer Inc. No permission required to reproduce, translate, display or distribute.

20	
  

EVALUATING THE RELATIONSHIP BETWEEN PHQ9 AND GLOBAL
Image 2: Global Pain Scale (GPS)
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